Pharmacological management of systemic sclerosis associated interstitial lung disease

References

• Giacomelli R, Liakouli V, Berardicurti O, et al. Interstitial lung disease in systemic sclerosis: current and future treatment. Rheumatol Int. 2017;37(6):853–863. DOI:10.1007/s00296-016-3636-7
   PubMed Web of Science ®Google Scholar
• Hoyles RK, Ellis RW, Wellsbury J, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis & Rheumatism. 2006;54(12):3962–3970. DOI:10.1002/art.22204
   PubMed Web of Science ®Google Scholar
• Morales-Cardenas A, Perez-Madrid C, Arias L, et al. Pulmonary involvement in systemic sclerosis. Autoimmun Rev. 2016;15(11):1094–1108. DOI:10.1016/j.autrev.2016.07.025
   PubMed Web of Science ®Google Scholar
• Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis. 2010;69(10):1809–1815. DOI:10.1136/ard.2009.114264
   PubMed Web of Science ®Google Scholar
• Hao Y, Hudson M, Baron M, et al. Early Mortality in a Multinational Systemic Sclerosis Inception Cohort. Arthritis & Rheumatology. 2017;69(5):1067–1077. DOI:10.1002/art.40027
   PubMed Web of Science ®Google Scholar
• Vonk MC, Broers B, Heijdra YF, et al. Systemic sclerosis and its pulmonary complications in the Netherlands: an epidemiological study. Ann Rheum Dis. 2009;68(6):961–965. DOI:10.1136/ard.2008.091710
   PubMed Web of Science ®Google Scholar
• Schurawitzki H, Stiglbauer R, Graninger W, et al. Interstitial lung disease in progressive systemic sclerosis: high-resolution CT versus radiography. Radiology. 1990;176(3):755–759. DOI:10.1148/radiology.176.3.2389033
   PubMed Web of Science ®Google Scholar
• Distler O, Assassi S, Cottin V, et al. Predictors of progression in systemic sclerosis patients with interstitial lung disease. Eur Respir J. 2020;55(5):1902026. DOI:10.1183/13993003.02026-2019
   PubMed Web of Science ®Google Scholar
• Steen VD, Lanz JK Jr., Conte C, et al. Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study. Arthritis Rheum. 1994;37(9):1290–1296.
   PubMed Web of Science ®Google Scholar
• Nihtyanova SI, Schreiber BE, Ong VH, et al. Prediction of pulmonary complications and long-term survival in systemic sclerosis. Arthritis & Rheumatology. 2014;66(6):1625–1635. DOI:10.1002/art.38390
   PubMed Web of Science ®Google Scholar
• Steen VD, Conte C, Owens GR, et al. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum. 1994;37(9):1283–1289.
   PubMedGoogle Scholar
• Silver KC, Silver RM. Management of Systemic-Sclerosis-Associated Interstitial Lung Disease. Rheum Dis Clin North Am. 2015;41(3):439–457.
   PubMedGoogle Scholar
• Solomon JJ, Olson AL, Fischer A, et al. Scleroderma lung disease. Eur Respir Rev. 2013;22(127):6–19.
   PubMedGoogle Scholar
• Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med. 2019;381(18):1718–1727. DOI:10.1056/NEJMoa1908681
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus Placebo in Scleroderma Lung Disease. N Engl J Med. 2006;354(25):2655–2666. DOI:10.1056/NEJMoa055120
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Roth MD, Clements PJ, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016;4(9):708–719. DOI:10.1016/S2213-2600(16)30152-7
   PubMed Web of Science ®Google Scholar
• Khanna D, Albera C, Fischer A, et al. An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial. J Rheumatol. 2016;43(9):1672–1679. DOI:10.3899/jrheum.151322
   PubMed Web of Science ®Google Scholar
• Distler O, Highland KB, Gahlemann M, et al. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. N Engl J Med. 2019;380(26):2518–2528. DOI:10.1056/NEJMoa1903076
   PubMed Web of Science ®Google Scholar
• Khanna D, Denton CP, Jahreis A, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSscinate): a phase 2, randomised, controlled trial. Lancet. 2016;387(10038):2630–2640. DOI:10.1016/S0140-6736(16)00232-4
   PubMed Web of Science ®Google Scholar
• Khanna D, Lin CJF, Furst DE, et al. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2020;8(10):963–974. DOI:10.1016/S2213-2600(20)30318-0
   PubMed Web of Science ®Google Scholar
• Sircar G, Goswami RP, Sircar D, et al. Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial. Rheumatology (Oxford). 2018;57(12):2106–2113.
   PubMed Web of Science ®Google Scholar
• Ebata S, Yoshizaki A, Oba K, et al. Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial. Lancet Rheumatol. 2021;3(7):e489–97. DOI:10.1016/S2665-9913(21)00107-7
   PubMedGoogle Scholar
• TV MT, Saunders P, Gibbons M, et al. Rituximab versus Cyclophosphamide for the Treatment of Connective Tissue Disease Associated Interstitial Lung Disease (RECITAL): A Sub-group Analysis of a Multi-centre Randomised Controlled Trial. Arthritis Rheumatol. 2022;74(suppl 9) [cited 2023 April 12]. Available from: https://acrabstracts.org/abstract/rituximab-versus-cyclophosphamide-for-the-treatment-of-connective-tissue-disease-associated-interstitial-lung-disease-recital-a-sub-group-analysis-of-a-multi-centre-randomised-controlled-trial/
   Google Scholar
• Nannini C, West CP, Erwin PJ, et al. Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies. Arthritis Research & Therapy. 2008;10(5):R124.
   PubMed Web of Science ®Google Scholar
• Goldin J, Elashoff R, Kim HJ, et al. Treatment of Scleroderma-Interstitial Lung Disease with Cyclophosphamide is Associated with Less Progressive Fibrosis on Serial Thoracic High-Resolution CT Scan Than Placebo. Chest. 2009;136(5):1333–1340. DOI:10.1378/chest.09-0108
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Elashoff R, Clements PJ, et al. Effects of 1-Year Treatment with Cyclophosphamide on Outcomes at 2 Years in Scleroderma Lung Disease. Am J Respir Crit Care Med. 2007;176(10):1026–1034. DOI:10.1164/rccm.200702-326OC
   PubMed Web of Science ®Google Scholar
• Roth MD, Tseng C-H, Clements PJ, et al. Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease. Arthritis & Rheumatism. 2011;63(9):2797–2808. DOI:10.1002/art.30438
   PubMed Web of Science ®Google Scholar
• Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76(8):1327–1339. DOI:10.1136/annrheumdis-2016-209909
   PubMed Web of Science ®Google Scholar
• Broen JCA, Van Laar JM. Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology. Nat Rev Rheumatol. 2020;16(3):167–178.
   PubMed Web of Science ®Google Scholar
• Volkmann ER, Tashkin DP, LeClair H, et al. Treatment with Mycophenolate and Cyclophosphamide Leads to Clinically Meaningful Improvements in Patient-Reported Outcomes in Scleroderma Lung Disease: results of Scleroderma Lung Study II. ACR Open Rheumatol. 2020;2(6):362–370. DOI:10.1002/acr2.11125
   PubMedGoogle Scholar
• Adler S, Huscher D, Siegert E, et al. Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group. Arthritis Research & Therapy. 2018;20(1).
   PubMedGoogle Scholar
• Bruni C, Tashkin DP, Steen V, et al. Intravenous versus oral cyclophosphamide for lung and/or skin fibrosis in systemic sclerosis: an indirect comparison from EUSTAR and randomised controlled trials. Clin Exp Rheumatol. 2020;38(3):161–168.
   PubMedGoogle Scholar
• Kundu S, Paul S, Hariprasath K, et al. Effect of Sequential Intravenous Pulse Cyclophosphamide-Azathioprine in Systemic Sclerosis-Interstitial Lung Disease: an Open-Label Study. Indian J Chest Dis Allied Sci. 2016;58(1):7–10.
   PubMedGoogle Scholar
• Berezne A, Ranque B, Valeyre D, et al. Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study. J Rheumatol. 2008;35(6):1064–1072.
   PubMed Web of Science ®Google Scholar
• Paone C, Chiarolanza I, Cuomo G, et al. Twelve-month azathioprine as maintenance therapy in early diffuse systemic sclerosis patients treated for 1-year with low dose cyclophosphamide pulse therapy. Clin Exp Rheumatol. 2007;25(4):613–616.
   PubMedGoogle Scholar
• Fernandez-Codina A, Walker KM, Pope JE, et al. Treatment algorithms for systemic sclerosis according to experts. Arthritis & Rheumatology. 2018;70(11):1820–1828.
   PubMed Web of Science ®Google Scholar
• Maher TM, Tudor VA, Saunders P, et al. Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial. Lancet Respir Med. 2023;11(1):45–54.
   PubMed Web of Science ®Google Scholar
• Lepri G, Avouac J, Airo P, et al. Effects of rituximab in connective tissue disorders related interstitial lung disease. Clin Exp Rheumatol. 2016;100(5):181–185.
   Google Scholar
• Hughes M, Denton CP, Khanna D. Rituximab for the treatment of systemic sclerosis-interstitial lung disease. Rheumatology (Oxford). 2021;60(2):489–491.
   PubMedGoogle Scholar
• NICE. Skin involvement in systemic sclerosis: rituximab2017.
   Google Scholar
• Khan K, Xu S, Nihtyanova S, et al. Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis. Ann Rheum Dis. 2012;71(7):1235–1242. DOI:10.1136/annrheumdis-2011-200955
   PubMed Web of Science ®Google Scholar
• De Lauretis A, Sestini P, Pantelidis P, et al. Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis. J Rheumatol. 2013;40(4):435–446. DOI:10.3899/jrheum.120725
   PubMed Web of Science ®Google Scholar
• Roofeh D, Lin CJF, Goldin J, et al. Tocilizumab Prevents Progression of Early Systemic Sclerosis-Associated Interstitial Lung Disease. Arthritis & Rheumatology. 2021;73(7):1301–1310. DOI:10.1002/art.41668
   PubMed Web of Science ®Google Scholar
• Khanna D, Lin CJF, Furst DE, et al. Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis-Interstitial Lung Disease: open-Label Extension of a Phase 3 Randomized Controlled Trial. Am J Respir Crit Care Med. 2022;205(6):674–684. DOI:10.1164/rccm.202103-0714OC
   PubMed Web of Science ®Google Scholar
• Suleman Y, Clark KEN, Cole AR, et al. Real-world experience of tocilizumab in systemic sclerosis: potential benefit on lung function for anti-topoisomerase-positive patients. Rheumatology (Oxford). 2021;60(8):3945–3946.
   PubMedGoogle Scholar
• Kuster S, Jordan S, Elhai M, et al. Effectiveness and safety of tocilizumab in patients with systemic sclerosis: a propensity score matched controlled observational study of the EUSTAR cohort. RMD Open. 2022;8(2):e002477.
   PubMedGoogle Scholar
• Isomura Y, Shirai Y, Kuwana M. Clinical worsening following discontinuation of tocilizumab in diffuse cutaneous systemic sclerosis: a single-centre experience in Japan. Rheumatology (Oxford). 2022;61(11):4491–4496.
   PubMed Web of Science ®Google Scholar
• Khanna D, Lescoat A, Roofeh D, et al. Systemic Sclerosis-Associated Interstitial Lung Disease: how to Incorporate Two Food and Drug Administration-Approved Therapies in Clinical Practice. Arthritis & Rheumatology. 2022;74(1):13–27. DOI:10.1002/art.41933
   PubMedGoogle Scholar
• Hinz B, Phan SH, Thannickal VJ, et al. The myofibroblast: one function, multiple origins. Am J Pathol. 2007;170(6):1807–1816.
   PubMed Web of Science ®Google Scholar
• Lehtonen ST, Veijola A, Karvonen H, et al. Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis. Respir Res. 2016;17(1):14. DOI:10.1186/s12931-016-0328-5
   PubMed Web of Science ®Google Scholar
• Ruwanpura SM, Thomas BJ, PG B. Pirfenidone: molecular mechanisms and potential clinical applications in lung disease. Am J Respir Cell Mol Biol. 2020;62(4):413–422.
   PubMed Web of Science ®Google Scholar
• Roth GJ, Binder R, Colbatzky F, et al. Nintedanib: from discovery to the clinic. J Med Chem. 2015;58(3):1053–1063. DOI:10.1021/jm501562a
   PubMed Web of Science ®Google Scholar
• Highland KB, Distler O, Kuwana M, et al. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial. Lancet Respir Med. 2021;9(1):96–106. DOI:10.1016/S2213-2600(20)30330-1
   PubMed Web of Science ®Google Scholar
• Matteson EL, Kelly C, Distler JHW, et al. Nintedanib in patients with autoimmune disease-related progressive fibrosing interstitial lung diseases: subgroup analysis of the INBUILD trial. Arthritis & Rheumatology. 2022;74(6):1039–1047. DOI:10.1002/art.42075
   PubMedGoogle Scholar
• Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071–2082. DOI:10.1056/NEJMoa1402584
   PubMed Web of Science ®Google Scholar
• van Laar JM, Farge D, Sont JK, et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA. 2014;311(24):2490–2498. DOI:10.1001/jama.2014.6368
   PubMedGoogle Scholar
• Sullivan KM, Goldmuntz EA, Keyes-Elstein L, et al. Myeloablative autologous stem-cell transplantation for severe scleroderma. N Engl J Med. 2018;378(1):35–47. DOI:10.1056/NEJMoa1703327
   PubMed Web of Science ®Google Scholar
• Kiboshi T, Kotani T, Konma J, et al. Comparison of therapeutic effects of combination therapy with prednisolone and tacrolimus or azathioprine on progressive interstitial pneumonia with systemic sclerosis. Mod Rheumatol. 2022;32(2):358–364. DOI:10.1080/14397595.2021.1918864
   PubMedGoogle Scholar
• Tochimoto A, Kawaguchi Y, Hara M, et al. Efficacy and safety of intravenous cyclophosphamide pulse therapy with oral prednisolone in the treatment of interstitial lung disease with systemic sclerosis: 4-year follow-up. Mod Rheumatol. 2011;21(3):296–301. DOI:10.3109/s10165-010-0403-6
   PubMed Web of Science ®Google Scholar
• Booth S, Moosavi SH, Higginson IJ. The etiology and management of intractable breathlessness in patients with advanced cancer: a systematic review of pharmacological therapy. Nat Clin Pract Oncol. 2008;5(2):90–100.
   PubMedGoogle Scholar
• Bajwah S, Colquitt J, Loveman E, et al. Pharmacological and nonpharmacological interventions to improve symptom control, functional exercise capacity and quality of life in interstitial lung disease: an evidence synthesis. ERJ Open Res. 2021;7(1):00107–2020. DOI:10.1183/23120541.00107-2020
   PubMedGoogle Scholar
• Visca D, Mori L, Tsipouri V, et al. Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a prospective, open-label, mixed-method, crossover randomised controlled trial. Lancet Respir Med. 2018;6(10):759–770. DOI:10.1016/S2213-2600(18)30289-3
   PubMed Web of Science ®Google Scholar
• Visca D, Tsipouri V, Mori L, et al. Ambulatory oxygen in fibrotic lung disease (AmbOx): study protocol for a randomised controlled trial. Trials. 2017;18(1):201. DOI:10.1186/s13063-017-1912-9
   PubMedGoogle Scholar
• Ekstrom M, Bajwah S, Bland JM, et al. One evidence base; three stories: do opioids relieve chronic breathlessness? Thorax. 2018;73(1):88–90.
   PubMed Web of Science ®Google Scholar
• Ekstrom M, Nilsson F, Abernethy AA, et al. Effects of opioids on breathlessness and exercise capacity in chronic obstructive pulmonary disease. A systematic review. Ann Am Thorac Soc. 2015;12(7):1079–1092.
   PubMed Web of Science ®Google Scholar
• Barnes H, McDonald J, Smallwood N, et al. Opioids for the palliation of refractory breathlessness in adults with advanced disease and terminal illness. Cochrane Database Syst Rev. 2016;3(3):CD011008.
   PubMedGoogle Scholar
• Jennings AL, Davies AN, Higgins JP, et al. A systematic review of the use of opioids in the management of dyspnoea. Thorax. 2002;57(11):939–944.
   PubMed Web of Science ®Google Scholar
• NHS Scotland. Scottish palliative care guidelines. 2021 [cited 2023 April 12]. https://www.palliativecareguidelines.scot.nhs.uk/
   Google Scholar
• Parshall MB, Schwartzstein RM, Adams L, et al. An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med. 2012;185(4):435–452. DOI:10.1164/rccm.201111-2042ST
   PubMed Web of Science ®Google Scholar
• Simon ST, Higginson IJ, Booth S, et al. Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults. Cochrane Database Syst Rev. 2016;10(10):CD007354.
   PubMedGoogle Scholar
• NICE. Palliative care - dyspnoea http://cks.nice.org.uk/topics/palliative-care-dyspnoea2022 [
   Google Scholar
• Hui D, Bohlke K, Bao T, et al. Management oF dyspnea in advanced cancer: aSCO Guideline. J Clin Oncol. 2021;39(12):1389–1411. DOI:10.1200/JCO.20.03465
   PubMed Web of Science ®Google Scholar
• Back I, Watson M, Armstrong P, et al. Palliative Care Adult Network Guidelines. https://book.Pallcare.info/index.Php2021
   Google Scholar
• Nihtyanova SI, Denton CP. Autoantibodies as predictive tools in systemic sclerosis. Nat Rev Rheumatol. 2010;6(2):112–116.
   PubMed Web of Science ®Google Scholar
• Bouros D, Wells AU, Nicholson AG, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med. 2002;165(12):1581–1586. DOI:10.1164/rccm.2106012
   PubMed Web of Science ®Google Scholar
• Volkmann ER, Tashkin DP, Sim M, et al. Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts. Ann Rheum Dis. 2019;78(1):122–130. DOI:10.1136/annrheumdis-2018-213708
   PubMed Web of Science ®Google Scholar
• Goh NS, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med. 2008;177(11):1248–1254. DOI:10.1164/rccm.200706-877OC
   PubMed Web of Science ®Google Scholar